CIK 0001422142 · Non-accelerated filer<br>Smaller reporting company
Whitehawk Therapeutics, Inc.
Sign in to watch- Ticker
- WHWK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 611547850
- Phone
- 551-321-2234
- Business address
- 2 HEADQUARTERS PLAZA, EAST BUILDING, 11TH FLOOR, MORRISTOWN, NJ, 07960
- Former names
- Aadi Bioscience, Inc., Aerpio Pharmaceuticals, Inc., ZETA ACQUISITION CORP II
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-13 | BALL BRYAN See remarks | Sale | −26,389 | $3.46 | $91K | 489,566 |
| 2026-04-10 | BALL BRYAN See remarks | Sale | −6,596 | $3.43 | $23K | 515,955 |
| 2026-04-09 | BALL BRYAN See remarks | Sale | −50,000 | $3.57 | $179K | 522,551 |
| 2026-04-09 | Lennon David James CHIEF EXECUTIVE OFFICER | Sale | −14,500 | $3.38 | $49K | 518,622 |
| 2026-04-08 | Lennon David James CHIEF EXECUTIVE OFFICER | Sale | −63,945 | $3.40 | $217K | 533,122 |
| 2026-04-07 | Lennon David James CHIEF EXECUTIVE OFFICER | Sale | −94,087 | $3.43 | $323K | 597,067 |
| 2026-04-06 | Lennon David James CHIEF EXECUTIVE OFFICER | Sale | −102,395 | $3.51 | $359K | 691,154 |
| 2026-04-02 | Lennon David James CHIEF EXECUTIVE OFFICER | Sale | −26,858 | $3.48 | $93K | 793,549 |
| 2026-04-01 | Lennon David James CHIEF EXECUTIVE OFFICER | Option exercise | +775,828 | 820,407 | ||
| 2026-04-01 | Lennon David James CHIEF EXECUTIVE OFFICER | Option exercise · Restricted Stock Units | −775,828 | 0 | ||
| 2026-04-01 | Lennon David James CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +831,148 | 831,148 | ||
| 2026-04-01 | Dugan Margaret Chief Medical Officer | Grant or award · Stock Option (right to buy) | +283,157 | 283,157 | ||
| 2026-04-01 | Dornan David Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +282,340 | 282,340 | ||
| 2026-04-01 | BALL BRYAN See remarks | Option exercise | +366,532 | 572,551 | ||
| 2026-04-01 | BALL BRYAN See remarks | Option exercise · Restricted Stock Units | −366,532 | 0 | ||
| 2026-04-01 | BALL BRYAN See remarks | Grant or award · Stock Option (right to buy) | +250,058 | 250,058 | ||
| 2026-04-01 | Giacobello Scott M. CHIEF FINANCIAL OFFICER | Option exercise | +473,902 | 502,002 | ||
| 2026-04-01 | Giacobello Scott M. CHIEF FINANCIAL OFFICER | Option exercise · Restricted Stock Units | −473,902 | 0 | ||
| 2026-04-01 | Giacobello Scott M. CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +300,677 | 300,677 | ||
| 2026-03-02 | Lennon David James CHIEF EXECUTIVE OFFICER | Sale | −5,100 | $3.31 | $17K | 44,579 |
Page 3 of 9 · 171 trades